Market Size of Global Single Cell Analysis Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 13.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Single Cell Analysis Market Analysis
The Single Cell Analysis Market is projected to register a CAGR of 13.10% during the forecast period (2022-2027).
The employment of single-cell analysis in the study of SARS-CoV2 viral infection is gaining importance during the COVID-19 pandemic, which is expected to significantly impact the studied market growth. According to the research article published in the American Journal of Physiology-Lung Cellular and Molecular Physiology, 2021, single-cell analysis through mass cytometry by time-of-flight (CyTOF) was used to study the changes in the peripheral blood mononuclear of COVID-19-infected patients. The application of a high throughput single-cell analysis technique helps in the evaluation of the immunological responses in COVID-19 patients. Additionally, as per the research study published in Cell, 2021, single-cell RNA sequencing was applied on 284 samples of COVID-19-infected patients and created an immune landscape with 1.46 million cells, which enabled the evaluation and correlation among different immune subtype changes with varied clinical features, such as age, sex, severity, and disease stages of COVID-19. Thus, given the ongoing research activities, by exploring the application of the single-cell analysis technique in the SARS-CoV2 virus study, the studied market is expected to have good opportunities for growth during the pandemic era.
The growth of the single-cell analysis market is attributed to the technological advancements in single-cell analysis products, increasing investments in cancer research, and growing biotechnology and biopharmaceutical industries in recent years.
Cancer is one of the main reasons of death across the world. The disease has witnessed significant growth in the past years, and it is expected to rise rapidly over the forecast period. As per the World Health Organization (WHO), key facts were updated in February 2022, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Each year, about 400 000 children develop cancer. The most common cancers vary between countries. Thus, the increasing incidence of cancer across the world rise the diagnosis rate and the demand for advanced diagnoses thereby accelerating the market. Additionally, according to International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. Circulating tumor cells are also gaining increasing clinical attention since they are likely to enable the monitoring of cancer progression and adjustment of treatment. The single-cell sequencing analysis has found its diagnostic and prognostic biomarkers.
Additionally, in clinical diagnostics, single-cell analysis is expected to standardize and automate workflows with valuable information for real-time monitoring of cancer and eventually new therapeutic strategies for the benefit of patients. This aspect is expected to lead to more efficient and better analysis. Therefore, increasing investments in cancer research is considered one of the major driving factors for the market over the forecast period.
However, the high cost of the single-cell analysis instruments is expected to restrain the studied market growth.
